MedPath

Role of Gut Microbiome in the Health Benefits

Not Applicable
Completed
Conditions
Normal Population
Interventions
Dietary Supplement: Beer
Registration Number
NCT05300165
Lead Sponsor
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
Brief Summary

Beneficial effects of moderate chronic consumption of beer have been extensively reported, however, the mechanisms have not been elucidated yet. Gut microbiota is an important mediator in the homeostasis of the host. Polyphenols act as bacterial substrates and modulators of the gut microbiota. Indeed, the investigators have previously observed that the chronic moderate consumption of red wine by metabolic syndrome patients triggered in an amelioration of the metabolic syndrome variables, and this effect was mediated, at least partially, by the interaction of the gut microbiota with the polyphenols of the red wine. In this manner, beer has a medium content of polyphenols. Thus, the investigators propose that the beneficial effects of moderate chronic consumption of beer could be because of the action of the gut microbiota with the beer polyphenols. The investigators are going to perform an intervention study in which normal volunteers will consume three different beer types with different content in polyphenols and it will be analyzed the gut microbiota profile (Metagenomics), metabolites (Metabolomics) and metabolic syndrome markers (gene expression, ELISA) to establish the correspondent relationships, trying to decipher the implication of the gut microbiota in the beneficial effects of moderate chronic consumption of beer.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
20
Inclusion Criteria
  • Age > 18 years
  • Usual consumer of Beer
Exclusion Criteria
  • being a non usual beer-consumer,
  • body mass index (BMI) > 40 kg m2.
  • acute or chronic infection, inflammatory disease or endocrine disorders; history of cancer; leukocytosis; anti-inflammatory, corticosteroid or hormone treatment.
  • history of alcohol abuse or drug dependence.
  • under a restrictive diet or a weight change ≥5 kg during the 3 months prior to the study.
  • antibiotic therapy, prebiotics, probiotics, synbiotics, vitamin supplements or any other medical treatment influencing intestinal microbiota during the 3 months before the start of the study or during the study.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Normal populationBeer20 participants representing a normal population will include a daily beer in their meals, changing the kind of beer every 2 weeks from alcohol-free lager beer, lager beer, or dark beer.
Primary Outcome Measures
NameTimeMethod
Changes in gut microbiotaBaseline, 2nd, 4th and 6th weeks visits

change from baseline in 16S rRNA amplicons determined in DNA from feces after 6 weeks

Secondary Outcome Measures
NameTimeMethod
Change in caloric consumptionBaseline and 6th weeks visits

change from baseline in the number of caloric consumption measured by an structured nutrient intake

Change in waist circumferenceBaseline and 6th weeks visits

Change from baseline in waist circumference (cm) after the completion of the trial

Change in glucose concentrationBaseline and 6th weeks visits

Change from baseline in serum glucose level after the completion of the trial

Change in HDL-cholesterol concentrationBaseline and 6th weeks visits

Change from baseline in serum HDL-cholesterol level after the completion of the trial

Change in triglycerides concentrationBaseline and 6th weeks visits

Change from baseline in serum triglycerides level after the completion of the trial

Change in blood pressureBaseline and 6th weeks visits

Change from baseline in blood pressure (systolic and diastolic) after the completion of the trial

Trial Locations

Locations (1)

Hospital Universitario Virgen de la Victoria

🇪🇸

Málaga, Spain

© Copyright 2025. All Rights Reserved by MedPath